Leveraging our own market resources, Relin cooperates with overseas manufacturers to select and introduce globally distinctive pharmaceutical products and technologies that address unmet clinical needs in China. The company completes the drug application in accordance with Chinese regulations and technical requirements. Meanwhile, it is also responsible for the post-approval change application and re-registration application of partner products in NMPA.

Our team has talents in pharmacy, pharmacology and clinical medicine, and we also have high-quality domestic CRO resources,so that can choose to cooperate with CRO to complete product registration together. Our team keeps up with the latest industry trends through continuous learning and training. We have a deep and thorough understanding of China's drug regulations and technical requirements. We are able to conduct accurate assessments of drug registration and tailor registration plans based on the unique characteristics of each product.